Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
TXG - 10x Genomics Inc
-0.22(-0.12%)9:00:00 PM 1/15/2021
10x Genomics is an American biotechnology company that designs and manufactures gene sequencing technology used in scientific research. It was founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin Ness. 10x Genomics was founded in 2012 by Serge Saxonov, Ben Hindson and Kevin Ness to create advanced testing equipment for use in cellular biology. Prior to starting the company, Saxonov was the founding architect, and director of research and development at 23andMe. Ness left 10x Genomics in December 2016 and in 2018, Justin McAnear, Tesla's former finance chief joined the company as CFO.
Stock Chart


  • RSI is at a high level of 76. A high level of RSI indicates the stock is overbought.
  • MACD is crossing MACD signal line at 3.6. MACD crossing signal line is bullish signal.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 


Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics

Related Peers

Stock news

    ROCE Insights For 10x Genomics

    During Q3, 10x Genomics's (NASDAQ:TXG) reported sales totaled $71.82 million. Despite a 65.54% in earnings, the company posted a loss of $65.25 million. In Q2, 10x Genomics brought in $42.91 million in sales but lost $39.42 million in earnings.What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of ...

    10x Genomics to Present at the 39th Annual J.P. Morgan Healthcare Conference

    PLEASANTON, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference. 10x Genomics’ management is scheduled to present on Monday, January 11 at 7:00 a.m. Pacific Time / 10:00 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: investors.10xgenomics.comAbout 10x Genomi...

    Did You Miss 10x Genomics' (NASDAQ:TXG) 88% Share Price Gain?

    Passive investing in index funds can generate returns that roughly match the overall market. But you can significantly...

    Is TXG A Good Stock To Buy According To Hedge Funds?

    The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]

    Stocks Close Lower But Pare Losses As This Index Outperforms

    The stock market escaped with minor losses Friday, as indexes rallied sharply in the final 20 minutes of trading. The IBD 50 performed relatively better than the indexes.

    These 5 Large-Cap Healthcare Stocks Had the Best Gains in 2020

    Big healthcare companies have become even larger in 2020. This company's developing potential new vaccines at great expense, but a lack of approved products to sell led Moderna to report a stunning $514 million loss in 2019.

    Apple, Twilio Lead Stocks Near Buy Points After Finding Bullish Support

    Your stocks to watch next week are five leaders that found support at their 50-day lines: They include Apple stock, Twilio and SolarEdge Technologies.

    Benzinga's Top Upgrades, Downgrades For December 2, 2020

    Upgrades * According to MoffettNathanson, the prior rating for Verizon Communications Inc (NYSE: VZ) was changed from Neutral to Buy. In the third quarter, Verizon Communications showed an EPS of $1.25, compared to $1.25 from the year-ago quarter. The current stock performance of Verizon Communications shows a 52-week-high of 62.22 and a 52-week-low of 48.84. Moreover, at the end of the last trading period, the closing price was at $60.57. * Wells Fargo upgraded the previous rating for S&P Gl...